このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Nudging Preventive Screening Via Message Framing and Bundling

2026年6月15日 更新者:Daniel Schwartz、University of Chile

The Effect of Message Framing and Screening Bundling on Preventive Screening Engagement: A Randomized Field Experiment

This study is a randomized controlled field experiment embedded in the medical institution Early Diagnosis Program in Chile. Participants with two exams pending (a cancer screening test and a chronic disease test for diabetes and dyslipidemia) will be randomly assigned across a 3 × 3 factorial design: three message framing conditions (Basic, Risk/Importance, Peace of Mind) crossed with three exam-type conditions (cancer screening only, chronic disease test only, or both exams). Participants with only a cancer screening pending will be assigned to the 3 framing conditions and be encouraged to get the cancer screening.

In both cases, participants are assigned to each experimental arm at twice the rate of an additional arm receiving the standard message currently used by the medical institution. This standard-message arm is included for operational purposes, is not part of the pre-specified analyses, and is thus not described in the "Arms and Intervention" section (or counted for "number of arms").

調査の概要

詳細な説明

The investigators will conduct a randomized controlled trial in the domain of preventive care engagement. Participants with two exams pending (a cancer screening test and a chronic disease test for diabetes and dyslipidemia) will be randomly assigned to a 3 × 3 factorial design. The first factor manipulates message framing, randomly assigning participants to receive either (i) a standard Whatsapp message, (ii) a Whatsapp message emphasizing age-related health risks and the importance of early detection, or (iii) a message emphasizing the potential peace of mind associated with completing screening. The second factor manipulates the type of exam highlighted in the outreach, randomly assigning participants to receive outreach focused on (i) cancer screening only, (ii) chronic disease testing only, or (iii) both cancer screening and chronic disease testing. Patients who have only one pending cancer exam are randomly assigned across the three message framing conditions only and are encouraged to get the cancer screening.

The experiment will test two sets of research questions.

Question 1. How does emphasizing different motivations for completing cancer screening affect patient engagement?

H1a. This study will test how messages emphasizing age-based health risks and the importance of early detection affect cancer screening engagement, relative to a basic message. Emphasizing health risks may increase perceived urgency and boost engagement; however, prior work on information avoidance suggests this framing may instead prompt avoidance of screening-related information and reduce engagement.

H1b. This study will test whether messages emphasizing that completing screening can bring peace of mind increase engagement relative to a basic message.

H1c. This study will test whether the effects of the two framing manipulations on cancer screening differ when the same messaging strategies are applied to chronic disease testing.

Question 2. How does combining recommendations for multiple preventive tests affect patient engagement? H2a. This study will examine the impact of bundling multiple tests (vs. single test) on patient engagement.

H2b. This study will test whether pairing cancer screening with a chronic disease testing recommendation affects cancer screening engagement. Recommending multiple tests may increase the perceived value of engaging with the healthcare system, boosting engagement with cancer screening; alternatively, patients may find the message more overwhelming or burdensome, reducing engagement with cancer screening.

H2c. This study will test whether pairing chronic disease testing with a cancer screening recommendation affects chronic disease testing engagement. Pairing may increase perceived value and make chronic disease testing seem less emotionally aversive, thus increasing engagement with chronic disease testing; alternatively, combining multiple recommendations may feel burdensome and reduce engagement with chronic disease testing.

The investigators will run ordinary least squares regressions (OLS) with robust standard errors to predict each outcome variable.

To test questions 1a and 1b, the study will focus on participants assigned to the cancer-screening-only condition, and the primary predictors of interest are indicators for whether participants are assigned to the Risk/Importance message condition or the Peace-of-Mind condition (with the Basic message condition as the reference group).

To test question 1c, the investigators will pool participants assigned to the cancer-screening-only and chronic-disease-only conditions and estimate models that include framing-condition indicators, an exam-type indicator, and their interactions.

To test question 2a, the investigators will focus on participants assigned to either cancer-screening-only condition, the chronic-disease-only condition, or the both-exams condition. The key independent variable will be an indicator for assignment to the both-exam condition (vs. the other two conditions combined as reference group). If this indicator is statistically significant, the investigators will compare the both-exam condition separately with cancer-screening-only condition and the chronic-disease-only condition.

To test question 2b, the study will focus on participants assigned to either the cancer-screening-only condition or the both-exams condition. The key independent variable will be an indicator for assignment to the both-exam condition.

To test question 2c, the study will focus on participants who received a message about chronic disease testing, including both those assigned to the chronic-disease-only condition and those assigned to the both-exams condition. The key independent variable will be an indicator for assignment to the both-exams condition.

Questions 1c-2c will only include participants with two exams pending (a cancer screening test and a chronic disease test for diabetes and dyslipidemia).

All regressions will be run with and without control variables, including number of pending exam fixed effects, age (continuous), gender, insurance type (public or private based on the local health insurance plans), and clinic or region indicators if available. For robustness, the investigators will conduct logit models as well.

Additionally, the study will explore whether the peace-of-mind message is more effective than the risk/importance message by comparing the coefficients on indicators for the risk/importance message and the peace-of-mind message in regressions described in the analysis.

Also, the investigators will examine whether the effects of the messaging manipulations on cancer screening engagement change when patients are simultaneously encouraged to complete both a cancer screening and chronic disease testing, relative to when they are only encouraged to complete a cancer screening. The regressions will include indicators for message types (risk/importance and peace of mind, relative to basic), an indicator for whether patients are recommended to take multiple tests (vs. just a cancer screening), and their interaction terms to predict (1) whether the patient indicates interest (by either clicking "Yes, I want help" or providing an equivalent affirmative response in Whatsapp) within 7 days, (2) whether the patient schedules the recommended cancer screening within 7 days, and (3) whether the patient completes the recommended cancer screening within 12 weeks.

Given that the experimental design addresses multiple distinct research questions, the analyses may ultimately be split across two papers focused on different sets of questions, particularly if including all analyses in a single paper would limit clarity or coherence.

The experiment is expected to last for 60 working days and reach 235,000 patients across all arms (including the standard-message arm that is not part of the study of interest). About 145,000 of these patients have two pending exams (cancer screening+chronic disease testing), and 90,000 patients have a pending cancer screening.

As an exploratory analysis, the investigators will examine patients' prior frequency of cancer and chronic disease screening as a potential moderator of intervention effects.

研究の種類

介入

入学 (推定)

235000

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Daniel Schwartz Associate Professor, Department of Industrial Engineering, Ph.D. Behavioral Decision
  • 電話番号:+56979984165
  • メール:daschwar@dii.uchile.cl

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Has at least one pending cancer screening (breast, colorectal, cervical, or prostate) within the contact window, as determined by the medical institution
  • Aged 21 to 74 years
  • Has a valid phone number on file
  • Eligibility is determined operationally before randomization (ex-ante)

Exclusion Criteria:

  • Participants whose WhatsApp message was not successfully delivered, as reported by the third-party software used by the medical institution.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:ヘルスサービス研究
  • 割り当て:ランダム化
  • 介入モデル:階乗代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Basic/Control × Cancer
Basic cancer screening message
Patients receive a WhatsApp message naming their recommended cancer screening exam and describing it as the test recommended for their age group.
アクティブコンパレータ:Basic/Control × chronic disease test
Basic chronic disease test message
Patients receive a WhatsApp message naming the recommended chronic disease test and describing it as the test recommended for their age group.
アクティブコンパレータ:Basic/Control × Both
Basic combined message
Patients receive a WhatsApp message naming both the recommended cancer screening and the chronic disease test, and describing them as the tests recommended for their age group.
実験的:Risk/Importance × Cancer
Risk framing cancer screening message
Patients receive a WhatsApp message naming their recommended cancer screening exam and emphasizing that (1) the recommendation is based on health risks common to their age group and (2) early detection can be life-saving
実験的:Risk/Importance × Chronic Disease Test
Risk framing chronic disease test message
Patients receive a WhatsApp message naming the recommended chronic disease test and emphasizing that (1) the recommendation is based on health risks common to their age group and (2) early detection can be life-saving.
実験的:Risk/Importance × Both
Risk framing combined message
Patients receive a WhatsApp message naming both exams and emphasizing that (1) the recommendation is based on health risks common to their age group and (2) early detection can be life-saving.
実験的:Peace of Mind × Cancer screening
Peace of mind framing cancer screening message
Patients receive a WhatsApp message naming their recommended cancer screening exam and emphasizing that getting the exam done on time will give them peace of mind about their health.
実験的:Peace of Mind × chronic disease Test
Peace of mind framing chronic disease test message
Patients receive a WhatsApp message naming the recommended chronic disease and emphasizing that getting the exam done on time will give them peace of mind about their health.
実験的:Peace of Mind × Both
Peace of mind framing combined message
Patients receive a WhatsApp message naming both exams and emphasizing that getting the exams done on time will give them peace of mind about their health.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Screening Engagement Response
時間枠:7 days after message delivery
Binary indicator of whether the patient clicks "Yes, I want help" or provides an equivalent affirmative response via WhatsApp within 7 days of receiving the message (1), or does not take either action (0). Used to test H1a, H1b, H1c, and H2a.
7 days after message delivery
Cancer Screening Appointment
時間枠:7 days after message delivery
Binary indicator of whether the patient schedules the recommended cancer screening exam within 7 days of receiving the message (1) or does not (0). Used to test H2b
7 days after message delivery
Chronic Disease Testing Appointment
時間枠:7 days after message delivery
Binary indicator of whether the patient schedules the recommended chronic disease test within 7 days of receiving the message (1) or does not (0). Used to test H2c.
7 days after message delivery

二次結果の測定

結果測定
メジャーの説明
時間枠
Screening Appointment Scheduling
時間枠:7 days after message delivery
Binary indicator of whether the patient schedules the specific test recommended in the message within 7 days of receiving it (1) or does not (0). Used to test H1a, H1b, and H1c.
7 days after message delivery
Screening Test Completion
時間枠:12 weeks after message delivery
Binary indicator of whether the patient completes the specific test recommended in the message within 12 weeks of receiving it (1) or does not (0). Used to test H1a, H1b, and H1c
12 weeks after message delivery
Any Test Appointment Scheduling
時間枠:7 days after message delivery
Binary indicator of whether the patient schedules any of the tests recommended in the message within 7 days of receiving it (1) or does not (0). Used to test H2a.
7 days after message delivery
Any Test Completion
時間枠:12 weeks after message delivery
Binary indicator of whether the patient completes any of the tests recommended in the message within 12 weeks of receiving it (1) or does not (0). Used to test H2a.
12 weeks after message delivery
Cancer Screening Completion
時間枠:12 weeks after message delivery
Binary indicator of whether the patient completes the recommended cancer screening exam within 12 weeks of receiving the message (1) or does not (0). Used to test H2b
12 weeks after message delivery
Chronic Disease Test Completion
時間枠:12 weeks after message delivery
Binary indicator of whether the patient completes the recommended chronic disease test within 12 weeks of receiving the message (1) or does not (0). Used to test H2c.
12 weeks after message delivery

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年6月8日

一次修了 (推定)

2026年9月8日

研究の完了 (推定)

2026年12月8日

試験登録日

最初に提出

2026年6月8日

QC基準を満たした最初の提出物

2026年6月8日

最初の投稿 (実際)

2026年6月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月17日

QC基準を満たした最後の更新が送信されました

2026年6月15日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data will not be shared due to institutional restrictions that prohibit data disclosure, even in anonymized form

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する